Key terms
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CUE news
Mar 13
5:01am ET
Analysts’ Top Healthcare Picks: Cooper Co (COO), Regeneron (REGN)
Mar 13
4:58am ET
Cue Biopharma initiated with a Buy at Jefferies
Feb 29
10:04am ET
Cue Biopharma presenting data on lead clinical asset CUE-101 at symposium
Feb 26
8:10am ET
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
Feb 20
7:45am ET
Cue Biopharma (CUE) Gets a Buy from Piper Sandler
No recent news articles are available for CUE
No recent press releases are available for CUE
CUE Financials
Key terms
Ad Feedback
CUE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CUE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range